CD86 and neoplasm: On the other hand, abnormal lipid accumulation in PBMCs subpopulations related to the innate immunity, such as dendritic cells (DC), have been shown to compromise the immune response at the local tumour microenvironment in patients with lung cancer (58) by reducing their antigen handling capacity, downregulating co-stimulating molecules such as CD86, and/or overexpressing tolerogenic cytokine IL-10 (59).